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ABSTRACT  
Background: Peripheral venous catheterisation is the most frequent invasive procedure performed 
in hospitalised patients; yet over 30% of peripheral venous catheters fail before treatment ends.  
Objectives: To assess the effects of peripheral venous catheter dressings and securement devices on 
the incidence of peripheral venous catheter failure. 
Data sources: We searched the Cochrane Wounds Group Register, The Cochrane Central Register of 
Controlled Trials, MEDLINE; EMBASE and CINAHL for any randomised controlled trials comparing 
different dressings or securement devices used to stabilise peripheral venous catheters. The 
reference lists of included studies were also searched for any previously unidentified studies.  
Results: We included six randomised controlled trials (1539 participants) that compared various 
dressings and securement devices (transparent dressings versus gauze; bordered transparent 
dressings versus a securement device; bordered transparent dressings versus tape; and transparent 
dressing versus sticking plaster). Trial sizes ranged from 50 to 703 participants.  The quality of 
evidence ranged from low to very low. Catheter dislodgements or accidental removals were lower 
with transparent dressings compared with gauze (two studies, 278 participants, risk ratio (RR) 0.40; 
95% confidence interval (CI) 0.17 to 0.92, P= 0.03%).  However, the relative effects of transparent 
dressings and gauze on phlebitis (RR 0.89; 95% CI 0.47 to 1.68) and infiltration (RR 0.80; 95% CI 0.48 
to 1.33) are unclear. A single study identified less frequent dislodgement or accidental catheter 
removal with bordered transparent dressings compared to a securement device (RR 0.14, 95% CI 
0.03 to 0.63) but more phlebitis with bordered dressings (RR 8.11, 95% CI 1.03 to 64.02). A 
comparison of a bordered transparent dressing and tape found more peripheral venous catheter 
failure with the bordered dressing (RR 1.84, 95% CI 1.08 to 3.11) but the relative effect on 
dislodgement was unclear. 
Conclusions: There is no strong evidence to suggest that any one dressing or securement product for 
preventing peripheral venous catheter failure is more effective than any other product.  All of the 
included trials were small, had high or unclear risk of bias for one or more of the quality elements we 
assessed, and wide confidence intervals, indicating that further randomised controlled trials are 
necessary. There is a need for suitably powered, high quality trials to evaluate the newer, high use 
products and novel – but expensive - securement methods, such as surgical grade glue. 
 
Keywords: Catheter-related infections, Evidence based practice, Occlusive dressings, Peripheral 
venous catheters, Vascular access devices 
 
3 
 
 
What is already known about the topic? 
 A peripheral venous catheter is typically used for short-term delivery of intravascular fluids 
and medications, however they often fail before treatment is complete. 
 Failure can occur due to inadequate securement of the device to the skin, resulting in the 
catheter falling out or complications such as phlebitis (irritation or inflammation to the vein 
wall), infiltration (fluid leaking into surrounding tissues) or occlusion (blockage).  
 Inadequate securement may also increase the risk of a catheter-related bloodstream 
infection, as the peripheral venous catheter moving in and out of the vein allows migration 
of organisms along the catheter and into the bloodstream.  
 Peripheral venous catheter dressings play a vital role in preventing catheter complications. 
However, despite the many dressings and securement devices available, the impact of 
different securement techniques for increasing peripheral venous catheter dwell time is still 
unclear. 
What this paper adds 
 There is no strong evidence to suggest that any dressing or securement product for 
peripheral venous catheters is more effective than any other. 
 We found limited evidence that catheters were less likely to fail due to dislodgement or 
accidental removal when a transparent dressing was used, compared with gauze. 
 Implications for the need of high quality research have been identified.  
 
 
BACKGROUND 
  
Peripheral venous catheters are flexible, hollow, plastic tubes that are inserted in a peripheral vein, 
most commonly the metacarpal vein of the hand, or alternatively the cephalic or basilica vein of the 
lower forearm [1, 2]. They are typically used for the short-term delivery of intravascular fluids and 
medications. Peripheral venous catheters are an essential element of modern medicine and their 
insertion is the most frequent invasive procedure performed in hospitals, with up to 80% of all 
hospitalised patients requiring one [3]. In the United States of America, an estimated 330 million 
peripheral venous catheters are sold each year [4]. However, catheters often fail before intravenous 
treatment is completed, which usually requires catheter replacement. Reported failure rates, or 
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unscheduled restarts, range from 33% to 69% [5-9]. Peripheral venous catheters fail for a wide range 
of reasons; the most commonly identified causes of failure are partial dislodgement or accidental 
removal, phlebitis (irritation or inflammation to the vein wall), occlusion (blockage), infiltration (fluid 
moving into surrounding tissue), leakage and, rarely, infection [6, 9, 10]. 
 
Effective catheter stabilisation may reduce the incidence of catheter failure and prevent problems 
associated with re-siting. For example, a peripheral venous catheter must be inserted through the 
patient’s skin, which normally acts as a protective barrier against bacteria entering the blood stream. 
Breaking the barrier may lead to phlebitis [2, 11] or, more rarely catheter related blood stream 
infection [12]. Repeated access attempts may also cause future venous access difficulties, including 
the need for a central venous catheter. In addition, waiting for a catheter to be re-sited can result in 
an interruption to the delivery of intravenous therapy and medicines with a potential increase in the 
duration of hospital stay and healthcare costs [2, 11, 13]. 
 
Despite a plethora of dressings and devices marketed for securing peripheral venous catheters, only 
one other systematic review has addressed the effectiveness of these products in preventing 
catheter related complications. The authors found that there was an increased risk of catheter tip 
infection when transparent dressings were used compared with gauze but no differences were 
found in the incidence of phlebitis or infiltration. However, the review was published before any 
randomised controlled trials in this area were available, so the inclusion criteria were wide, including 
abstracts, letters and observational studies [14]. The most effective method for securing peripheral 
venous catheters remains unclear, so there is a need to provide guidance for clinicians by synthesise 
evidence from randomised controlled trials on the efficacy of devices and dressings that are used to 
secure peripheral catheters.  
 
OBJECTIVE 
To assess the effects of peripheral venous catheter dressings and securement devices on the 
incidence of peripheral venous catheter failure. 
METHODS 
We included randomised controlled trials or cluster randomised trials (where the cluster 
represented randomisation at the ward or hospital level), comparing different dressings or 
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securement devices for the stabilisation of peripheral venous catheters. Cross-over trials were 
ineligible for inclusion, unless data for the first treatment period could be obtained. Participants 
included any patients in any setting who required a peripheral venous catheter. The intervention of 
interest was any dressing or securement device that was compared with another dressing or 
securement device, for the protection or stabilisation of a peripheral venous catheter. Dressings or 
securement devices that were made from any type of product (e.g. polyurethane, gauze) were 
eligible. Our primary outcomes of interest were catheter failure (defined as any reason for the 
unplanned removal of the catheter); and adverse events associated with the dressing or device. Our 
secondary outcomes included the incidence of specific reasons for catheter failure (e.g. 
dislodgement/accidental removal; phlebitis; infiltration; occlusion); time to catheter failure and 
costs. 
 
Search strategy 
In April 2015 we conducted structured searches in the following electronic databases: the Cochrane 
Wounds Group Specialised Register (searched 8 April 2015); the Cochrane Central Register of 
Controlled Trials (CENTRAL; 2015, Issue 3); Ovid MEDLINE (1946 to March 7, 2015); Ovid MEDLINE 
(In-Process & Other Non-Indexed Citations, March 7, 2015); Ovid EMBASE (1974 to March 7, 2015); 
and EBSCO CINAHL (1982 to March 8, 2015). For the search strategy used in the Cochrane Central 
Register of Controlled Trials, refer to Supplementary Table 1. We adapted this strategy to search 
Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL. We combined the Ovid MEDLINE search with the 
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- 
and precision-maximising version [15]. We combined the EMBASE search with the Ovid EMBASE 
filter developed by the UK Cochrane Centre [15]. We combined the CINAHL searches with the trial 
filters developed by the Scottish Intercollegiate Guidelines Network [16]. We did not restrict studies 
with respect to language, date of publication or study setting. We searched the following clinical 
trials registries: ClinicalTrials.gov (http://www.clinicaltrials.gov/); WHO International Clinical Trials 
Registry Platform (http://apps.who.int/trialsearch/Default.aspx); and EU Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/). We searched the reference lists of all relevant publications 
we retrieved for other studies that had not been identified by the search methods described above. 
Study selection 
Studies were included in the review if two review authors (NM and JW) independently agreed that 
they met the inclusion criteria. 
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Data collection process 
Data was extracted independently by one author (NM), using a standardised form and checked for 
accuracy by a second author (JW). The extracted information was entered into the Cochrane 
Collaboration review RevMan software by NM, and JW checked the data for accuracy. If information 
regarding any part of the data was unclear, we attempted to contact the study authors of the 
original reports and asked them to provide further details. We extracted the following information: 
participant characteristics and exclusions; type of dressing or securement device; setting; study 
dates; unit of investigation (participant or catheter); interventions; length of follow-up; information 
about ethics approval, consent and any declared conflicts of interest; and outcomes. 
 
Assessment of risk of bias in included studies 
Independently, two review authors (NM and JW) assessed the included studies for risk of bias using 
a standardised tool [17]. This tool addresses seven specific domains, namely: sequence generation; 
allocation concealment; blinding of participants and personnel; blinding of outcome assessment; 
incomplete outcome data; selective outcome reporting; other possible problems that could put the 
study at risk of bias, such as unequal numbers in the study groups or early stopping of a trial. 
Disagreements between the two review authors (NM and JW) were discussed and resolved by 
consensus. An overall risk of bias assessment for each study was completed (see Supplementary 
Figure 1). 
 
Data analysis 
For dichotomous outcomes, we calculated risk ratio (RR) plus 95% confidence intervals (CI). For 
continuous outcomes we planned to calculate the mean difference (MD) plus 95% CI. We planned to 
analyse any time-to-event data (e.g. time to development of phlebitis) using hazard ratios; we did 
not analyse time-to-event data that were incorrectly presented as continuous data. 
 
We expected to find a number of studies that reported on multiple devices per participant, which 
were unadjusted for clustering. In such cases we planned to contact the study authors and attempt 
to obtain: patient-level data or results; data or results for one device per participant; or device-level 
data. If we were unsuccessful in obtaining the additional data required, then we would exclude the 
study from the meta-analysis.  
 
We identified the missing data for each study and attempted to contact the study authors to obtain 
the information necessary for analysis. Where the data could not be obtained, we performed an 
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analysis on the available data. Data was pooled for meta-analysis as fixed effects models. The Chi2 
test was used to assess statistical heterogeneity, with significance set at a P value of less than 0.10. 
The I2 statistic was also calculated to quantify heterogeneity across studies [18] (heterogeneity 
declared at >50%) [18].  
 
The following subgroup and sensitivity were planned where data was available: children (under 16 
years of age) and adults; continuous versus intermittent IV therapy; additional bandaging versus 
dressing or securement device alone; adequate vs. inadequate concealment of allocation; size of 
studies (greater or fewer than 100 patients); follow-up period of less or more than 48 hours; missing 
data - best/worst case scenarios. 
 
RESULTS 
Figure 2 shows the flow of studies through the selection process. 
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Figure 2 PRISMA flow chart  
 
We identified 56 references (see Figure 2). After reviewing titles and abstracts, we eliminated 47 
clearly irrelevant references. We retrieved full text copies of the remaining nine potentially eligible 
papers. We included six of these trials [19-24], and excluded one trial [25]. Four further trials are 
awaiting classification [26-29]. We also identified one trial on ClinicalTrials.gov but this was a 
prospective cohort study. 
 
Included studies 
We included six trials in this review, with a total of 1539 participants, and trial sizes ranging from 50 
to 703. Characteristics of the included studies are in Table 2. Two trials were conducted in the 
United States of America [19, 24], two in Spain [20, 23], one in Italy [21], and one in England [22]. All 
of the trials were conducted in a single-centre, acute inpatient setting with either paediatric only 
[22], adult and paediatric [21] or adult only participants [19, 20, 23, 24]. Among the trials recruiting 
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adults, the mean participant age ranged between 55 and 60 years. The majority of trials were 
conducted within a 10-year time frame, between 2000 and 2010 [19-21, 23], the Tripepi-Bova et al 
trial [24] was undertaken between 1994 and 1995. It is unclear when the Livesley et al study [22] 
was undertaken, but results were published in 1993. Evidence of institutional ethics approval was 
available for four of the trials [19-21, 24], and participant consent in four trials [19-22]. Tripepi-Bova 
et al [24] stated that consent was not required, as both dressings were considered non-
experimental. One study acknowledged industry sponsorship [19]. 
 
Four comparisons of interventions were reported in the included trials. The first comparison was of 
transparent dressings compared with gauze [20, 23, 24]. The intervention dressing used by Chico-
Padron et al [20] was described simply as a transparent dressing, Rodriguez et al [23] used a 3M 
Tegaderm® Film Dressing and the transparent dressing in the Tripepi-Bova et al study [24] was Smith 
& Nephew’s Opsite®. The second comparison was of a bordered transparent dressing compared to a 
securement device [19], and the dressing used in the intervention arm was 3M Tegaderm IV®. The 
third comparison was of a bordered transparent dressing (Veni-Guard® Breathable I.V. Dressing) 
assessed against tape [22], and, the final comparison was of a transparent dressing – described as a 
sterile dressing made of highly permeable polythene film, with latex-free hypoallergenic adhesive - 
compared with sticking plaster [21]. 
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Table 2 Key characteristics of included studies  
Author Method Participants Interventions Outcomes 
Bausone-Gazda et al [19]  Single-centre randomised 
controlled trial in the 
United States of America 
302 medical-surgical 
patients with an 
anticipated 96-hour need 
for a peripheral venous 
catheter. 
Bordered transparent group: BD 
Nexiva Closed IV Catheter System 
with the insertion site covered 
with a 3M Tegaderm IV 
securement dressing. 
Securement device group: B Braun 
Introcan Safety Catheter with a 
Bard StatLock IV Ultra Stabilization 
Device and the insertion site 
covered by a transparent dressing.  
 
Catheter failure; 
Dislodgement/accidental removal;                                      
Phlebitis; 
 
 
Chico-Padron et al [20] Single-centre randomised 
controlled trial in Spain 
50 patients admitted to 
general surgical ward and 
coronary intensive care 
unit. 
 
Transparent dressing group: sterile 
strip and transparent dressing. 
Gauze dressing group: sterile strip 
and gauze dressing. 
Dislodgement/accidental removal;                                      
Phlebitis;                                        
Infiltration;                                 
Cost; 
Forni et al [21] Single-centre randomised 
controlled trial in Italy 
703 paediatric and adult 
patients with 
orthopedic/traumalogical 
problems and orthopaedic 
oncological disease. 
 
Transparent dressing group: 
transparent sterile dressing made 
of highly permeable polythene 
film, with latex free hypoallergenic 
adhesive. 
Sticking plaster group: non sterile, 
elastic, vellum-like polyester lined 
sticking plaster with hypoallergenic 
Dislodgement/accidental removal;                                      
Phlebitis;                                        
Infiltration;                                       
Occlusion;  
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adhesive. 
 
Livesley et al [22] Single-centre randomised 
controlled trial in England 
155 paediatric patients 
form a paediatric university 
teaching hospital 
(excluding intensive care, 
metabolic unit and bone 
marrow transplant unit) 
 
Bordered transparent group: 
Venigard
®
 bordered transparent 
dressing was used to cover the 
insertion site. A ‘T’ – piece 
extension set with a luer-lock  was 
used between the cannula hub and 
extension set or administration set. 
Tape dressing group: Non sterile 
tape was used to secure the 
cannula with an extension or 
administration set fixed to the hub 
of the catheter. 
Catheter failure; 
Dislodgement/accidental removal;                                       
     
Rodriguez et al [23] Single-centre randomised 
controlled trial in Spain 
100 patients participated in 
this trial 
Transparent dressing group: 3M 
Tegaderm transparent™ dressing 
Gauze dressing group: gauze 
dressing 
Phlebitis;                                        
Infiltration;                                        
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Tripepi-Bova et al [24] Single-centre randomised 
controlled trial in the 
United States of America 
229 patients from 6 units 
(2 medical cardiology, 
surgical cardiology, general 
internal medicine, 
orthopaedic and 
neurological intensive 
care). 
 
Transparent dressing group: 
Opsite®(Smith & Nephew, Quebec, 
Canada) applied directly over the 
insertion site. Tape applied to 
secure the intravenous tubing. 
Gauze dressing group:  Mirasorb 
®sponges (5 cm x 5 cm; Johnson & 
Johnson Medical Inc, Arlington, 
Texas) applied directly over the 
insertion site. Tape applied to 
secure the intravenous tubing. 
Dislodgement/accidental removal;                                      
Phlebitis;                                        
infiltration;                                        
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Methodological quality of studies 
Five of the investigators reported that they used computer generated randomisation [19, 21, 22, 24] 
or a randomly generated number list [20]. Rodriguez et al [23] did not describe the method used to 
generate the allocation sequence in the trial. Two studies [21, 24] stated that sealed envelopes were 
used, but only Forni et al [21] stated that the envelopes were also opaque and numbered. One trial 
[19] stated that “randomization assignment was not provided to the venous access device team 
nurse until the subject had been assessed and the site determination had been made” but it was 
unclear how the allocation details were concealed. Allocation concealment was not described in 
reports of the other three trials [20, 22, 23]. 
 
The appearance of dressings and securement devices were dissimilar in all of the trials so it was not 
possible to blind participants or personnel in any of the included trials. Outcome assessors were not 
blinded to the intervention in any of the included trials. Two investigators had outcome assessments 
conducted by ward nursing staff [22, 24], and another two did not identify clearly who performed 
the outcome assessments [20, 23]. Forni et al [21] had assessments performed by research nurses 
and Bausone-Gazda et al [19] had assessments performed by the hospital’s vascular access device 
team who also recruited the participants. 
 
Four trials reported complete outcome data [19-21, 24]. In one study [22], the number of 
participants originally enrolled in the trial was not stated but group numbers reported in the results 
were quite unequal (69:86). This disparity may suggest either post-randomisation exclusions, drop 
outs or a failure to report. One trial [23] was translated from Spanish to English; it was unclear from 
the translation whether data were incomplete and, if they were, whether losses had been explained. 
Study protocols were not available for any of the included trials, so it was impossible to determine if 
there was selective reporting bias. Two trials had unequal numbers in the intervention groups [20, 
24], and one trial stopped early [19]. In this trial, which was manufacturer sponsored, the sample 
size was estimated to be 400 but only 302 patients were recruited. The reason provided for stopping 
the trial early was “enrolment issues and the project timeline”. 
 
Effectiveness of interventions 
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Transparent dressings versus gauze  
Three trials compared transparent dressings versus gauze but none of the trials assessed our primary 
outcomes. Of the secondary outcomes, two trials (278 participants) reported on 
dislodgement/accidental removal [20, 24]; the evidence from these trials was assessed as very low 
quality; the method used for group allocation was unclear and neither the personnel nor the 
outcome assessors were blinded to group allocation. When results were combined, there were 
significantly fewer instances of dislodgement/accidental removal in the transparent dressing group 
(7/136) than in the gauze group (19/142) (RR 0.40; 95% CI 0.17 to 0.92) (Figure 3). However, the 
confidence interval was wide suggesting that further trials are needed to decrease the uncertainty 
around the effect size (Figure 3). Three trials (379 participants) at high risk of bias for at least two 
domains in the risk of bias tool, reported phlebitis as an outcome [20, 23, 24]. There was no 
evidence of a difference in rates of phlebitis between transparent dressings (16/184) and gauze 
(17/195) (RR 0.89; 95% CI 0.47 to 1.68). Infiltration was reported in all three trials for this 
comparison (379 participants) [20, 23, 24]. All trials were assessed as being at high risk of bias. When 
results were combined, there was no evidence of a difference between groups in rates of infiltration 
(transparent dressing 21/ 184, gauze 29/195; RR 0.80; 95% CI 0.48 to 1.33). None of our other pre-
determined secondary outcomes were assessed. Heterogeneity was not an issue for this comparison 
with I2 values below 30% for all outcomes. 
 
 
 
Figure 3. Meta-analysis of studies reporting dislodgement or accidental removal when a transparent dressing 
was compared with a gauze dressing. 
 
 
Bordered transparent dressing compared with a securement device 
Only one trial, judged to be at high risk of performance and detection bias and at unclear risk for 
allocation concealment compared bordered transparent dressings with a securement device [19]. 
This trial included 302 participants, 150 in the bordered transparent dressing group and 152 in the 
securement device group. There was no evidence of a difference between groups for one of our 
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primary outcome, peripheral venous catheter failure from any cause, (bordered transparent dressing 
50/150 and securement device 59/152; RR 0.86; CI 0.64 to 1.16). Results for three of our secondary 
outcomes were reported. The bordered transparent dressing group had fewer instances of 
dislodgement or accidental removal than the securement device group (P value 0.008; bordered 
transparent dressing 2/150 and securement device 14/152; RR 0.14; 95% CI 0.03 to 0.63). The 
securement device group had fewer cases of phlebitis compared with the bordered transparent 
dressing group (bordered transparent dressing 8/150 and securement device 1/152; RR 8.11; 95% CI 
1.03 to 64.02). Very wide confidence intervals for this comparison indicate a very high level of 
uncertainty around the effect size. Type of dressing showed no evidence of effect on the frequency 
of infiltration between groups (bordered transparent dressing 21/150 and securement device 
27/152; RR 0.79; 95% CI 0.47 to 1.33). Nor were there any differences between groups in terms of 
time to catheter failure [19].  
 
Bordered transparent dressing compared with tape  
One trial, which was assessed as being at high risk of bias (the method used for group allocation was 
unclear and neither the personnel nor the outcome assessors were blinded to group allocation), 
compared a bordered transparent dressing and tape [22]. This trial included 153 participants with a 
large disparity in the number of participants in each group (68 in the bordered transparent dressing 
group and 85 in the tape group). No explanation was provided for the 20% difference in group 
numbers. Peripheral venous catheter failure occurred less frequently in the tape group than the 
bordered transparent dressing group (bordered transparent dressing 25/68 and tape 17/85; RR 1.84; 
95% CI 1.09 to 3.11). There was no evidence of a difference in rates of dislodgement or accidental 
removal for either securement method nor of time to catheter failure [22]. 
 
Transparent dressing compared with sticking plaster  
Forni et al [21] was the only trial to compare a transparent dressing with a sticking plaster. We 
contacted the author who provided data for the first catheter per patient. This trial was at high risk of 
performance and detection bias and included 706 participants; 346 in the transparent dressing group 
and 357 in the sticking plaster group. Only one of our primary outcomes was reported, adverse 
events. These were five cases of allergy, three cases in the transparent dressing group and two in the 
sticking plaster group. However, information about how the allergic reaction presented and if further 
follow-up management of the allergy was required was not available [21]. For our secondary 
outcomes there was no evidence of a difference between groups for dislodgement/accidental 
removal; phlebitis; infiltration or occlusion.   
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Table 3 Analysis for the primary outcome of peripheral venous catheter failure due to catheter 
complications for all four comparisons  
Outcome or subgroup title No. of 
studie
s 
No. of 
participants 
Statistical method Effect size 
 
Peripheral venous catheter failure 
 Transparent dressing versus gauze 
 Bordered transparent dressing 
versus securement device 
 Bordered transparent dressing 
versus tape 
 Transparent dressing versus sticking 
plaster 
 
Nil 
1 
 
1 
 
Nil 
 
 
302 
 
153 
 
 
Risk Ratio (M-H, Fixed, 95% 
CI) 
 
Risk Ratio (M-H, Fixed, 95% 
CI) 
 
 
0.86 (0.64, 
1.16) 
 
1.84 (1.09, 
3.11) 
 
 
 
DISCUSSION 
Although the main purpose of peripheral venous catheter dressings and securement devices is to 
prevent catheter failure, only two trials addressed this outcome. One showed no evidence of a 
difference between a bordered transparent dressing and a securement device [19], while in the 
other trial [22], tape alone was almost twice as effective in preventing catheter failure compared 
with a bordered transparent dressing (RR 1.84; 95% CI 1.09 to 3.11). However, in this trial, we were 
unable to determine reasons for a disparity in the number of participants in each group (68 
bordered transparent dressing group and 85 tape group), so the results are inconclusive. 
 
All of the trials reported on one or more of the individual components of the composite primary 
outcome. Transparent dressings, with or without a border, were more effective in preventing 
dislodgement or accidental removal compared with gauze or a securement device [19, 20, 24], but 
transparent dressings showed no evidence of benefit for any of the other secondary outcomes when 
compared with tape or sticking plaster [21, 22]. Phlebitis was eight times more likely to occur when a 
bordered transparent dressing was compared with a securement device (RR 8.11; 95% CI 1.03 to 
64.02). However, extremely the wide confidence intervals for this result indicate that there is a great 
deal of uncertainty about the effect size. No evidence of a difference in phlebitis rates were shown 
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when any other dressings or devices were compared. Nor did any of the five trials measuring 
infiltration show any evidence of effect; irrespective of the dressing or device used to secure the 
catheter. Similarly, catheter occlusion rates showed no evidence of a difference when transparent 
dressings were compared with sticking plaster [21]. Cost was the only other outcome measured; 
these results indicated that bordered transparent dressings were a cheaper securement method 
compared to a securement device. None of the single study comparisons was adequately powered 
to detect differences, so there is a possibility that type two errors could have occurred. 
 
Dressings and securement devices for peripheral intravenous catheters continue to evolve, with new 
products regularly coming on to the market. A limited number of randomised controlled trials were 
available for this review, so most of the comparisons in the review had only one study contributing 
to the results. Consequently, some products in common use were not represented in this review. 
Another restriction on the completeness and applicability of the review is that many of our primary 
and secondary outcomes were poorly reported. For example, only two trials assessed our primary 
outcome of peripheral venous catheter failure - the prevention of which is the main reason for 
applying a dressing or securement device. Moreover, other outcomes of interest, such as entry site 
local infection, catheter related blood stream infection and patient satisfaction were not reported at 
all. These omissions make the selection of an effective securement device difficult for healthcare 
providers. Finally, participants for this review were drawn largely from adult populations and were 
predominately from general medical/surgical wards and orthopaedic specialties. Emergency 
departments and general cancer care areas, which are frequent users of peripheral venous 
catheters, were not included in this review. Additionally, the review included only those patients 
admitted to acute hospitals settings, consequently, the applicability of results to other settings, such 
as community and rehabilitation facilities remains unknown. 
 
The quality of the evidence was assessed as very low, using the GRADE approach [30]. In summary, 
only one trial reported sufficient information for us to judge allocation concealment [21]. It was not 
possible to blind personnel and participants to the intervention received, as dressings were clearly 
different. In one trial the participants also received a different peripheral venous catheter and 
extension tubing according to their randomised dressing or securement device [19], a co-
intervention that may have had an impact on the results. Livesley et al [22] reported unequal 
numbers in the intervention groups with more participants receiving a gauze dressing than a 
bordered transparent dressing, this may indicate incomplete follow-up or incomplete reporting. One 
of the included trials disclosed receiving manufacturer sponsorship [19]. In all of the trials except 
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one [21], the outcomes from the number of participants analysed matched the number randomised. 
We could not determine whether this was due to ’available case’ reporting or whether there were, 
indeed, no losses to follow-up.  
 
In all of the pooled outcomes, heterogeneity was less than 30% indicating that, although populations 
and interventions varied slightly across studies, they were similar enough to combine results. 
Confidence intervals were wide in the pooled outcomes, but few studies were included and sample 
sizes were small. Imprecise results may reflect differences in intervention products and outcome 
definitions. Confidence intervals were also wide in the single studies that showed evidence of effect.  
 
We feel confident that our comprehensive electronic searches identified all existing, published 
randomised controlled trials addressing the review question, helping to limit bias in the review 
process. One manufacturer sponsored, observational study, comparing two different catheter 
stabilising systems was identified through Clinical trials.com. The trial was completed in 2013 but 
results have not been published. The scant contribution of the six included trials, in the face of such 
wide use and evolving products for peripheral venous catheter stabilisation, seems unusual. This 
may or may not indicate publication bias. There were fewer than 10 studies, so we did not construct 
a funnel plot. In terms of potential biases in the review process itself, clearly described procedures 
were followed to prevent this occurrence. A careful literature search was conducted, and the 
methods used are transparent and reproducible.  
 
One other systematic review has addressed a similar topic but inclusion criteria were wider [14]. The 
focus of the review was to compare transparent polyurethane dressing with a gauze dressing for 
peripheral catheters. Two of the outcomes assessed in the review [14] were the same as ours 
(phlebitis and infiltration), so we were able to compare results. Although the inclusion criteria were 
quite different, our results for these outcomes were in agreement and no between group 
differences were found for either phlebitis or infiltration. Similarly, in an earlier, quasi-randomised 
controlled trial of 598 participants, published by the same author, no statistically significant 
differences were found in the rate of phlebitis between a transparent polyurethane group and a 
cotton gauze group [31]. 
 
CONCLUSIONS 
There is no strong evidence to suggest that any one dressing or securement product for peripheral 
catheters is more effective than any other dressing. We found limited evidence that catheters were 
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less likely to fail due to dislodgement or accidental removal when a transparent dressing was used, 
compared with gauze. Other positive outcomes, favouring one dressing over another, were based on 
single studies, so further trials are required to support their findings. All of the included trials were 
small, had either high or unclear risk of bias for one or more of the quality elements we assessed, 
and wide confidence intervals, indicating that further randomised controlled trials are necessary.  
 
Products included in this review were limited, as were the outcomes assessed. There is a need for 
suitably powered, high quality trials to evaluate the newer, high use products and novel – but 
expensive - securement methods, such as surgical grade glue. Following items in the CONSORT 
statement when planning and reporting future trials, would provide more transparency for those 
assessing the quality of the studies. Important outcomes such as catheter-related bloodstream 
infection, entry site local infection, skin damage and the patient’s satisfaction with the product were 
not available for assessment in this review, but should be included in future studies. Given the large 
cost difference between different dressings and securement devices, we believe it is important to 
include a planned economic analysis, including the number of dressing changes required and staff 
time involved. This would enable decision makers to make rational and cost effective choices when 
purchasing dressings and devices for peripheral catheter securement. 
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Table 1 Search strategy for the Cochrane Central Register of Controlled Trials 
MEDLINE: 
1 exp Catheterization, Peripheral/ (8005) 
2 (peripheral venous catheter* or PVC).tw. (3869) 
3 1 or 2 (11753) 
4 exp Occlusive Dressings/ (3380) 
5 (securement device* or Statlock or Hubguard).tw. (27) 
6 ((occlusive or gauze or tape or polyurethane or permeable or nonpermeable or non-permeable or 
transparent or antimicrobial) adj3 dressing$).ti,ab. (1506) 
7 (opsite or tegaderm or micropore or hypafix).tw. (1015) 
8 or/4-7 (5250) 
9 3 and 8 (59) 
EMBASE: 
1 exp Catheterization, Peripheral/ (132218) 
2 (peripheral venous catheter* or PVC).tw. (6567) 
3 1 or 2 (138442) 
4 exp Occlusive Dressings/ (506) 
5 (securement device* or Statlock or Hubguard).tw. (54) 
6 ((occlusive or gauze or tape or polyurethane or permeable or nonpermeable or non-permeable or 
transparent or antimicrobial) adj3 dressing$).ti,ab. (2149) 
7 (opsite or tegaderm or micropore or hypafix).tw. (1738) 
8 or/4-7 (4134) 
9 3 and 8 (144) 
10 Randomized controlled trials/ (44267) 
11 Single-Blind Method/ (18729) 
12 Double-Blind Method/ (121977) 
13 Crossover Procedure/ (39367) 
14 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or 
allocat$ or volunteer$).ti,ab. (1333989) 
15 (doubl$ adj blind$).ti,ab. (149615) 
16 (singl$ adj blind$).ti,ab. (14549) 
17 or/10-16 (1399725) 
18 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or 
animal cell/ or nonhuman/ (20843564) 
19 human/ or human cell/ (15195392) 
20 and/18-19 (15148733) 
21 18 not 20 (5694831) 
22 17 not 21 (1209068) 
23 9 and 22 (50) 
CINAHL: 
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S22S9 AND S21 
S21S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 
S20TX allocat* random* 
S19(MH "Quantitative Studies") 
S18(MH "Placebos") 
S17TX placebo* 
S16TX random* allocat* 
S15(MH "Random Assignment") 
S14TX randomi* control* trial* 
S13TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or 
TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 
S12TX clinic* n1 trial* 
S11PT Clinical trial 
S10(MH "Clinical Trials+") 
S9(S4 OR S5 OR S6 OR S7) AND (S3 AND S8) 
S8S4 OR S5 OR S6 OR S7 
S7TI ( (opsite or tegaderm or micropore or hypafix) ) OR AB ( (opsite or tegaderm or micropore or 
hypafix) ) 
S6TI ( ((occlusive or gauze or tape or polyurethane or permeable or non permeable or non-
permeable or transparent or antimicrobial) n3 dressing*) ) OR AB ( ((occlusive or gauze or tape or 
polyurethane or permeable or non permeable or non-permeable or transparent or antimicrobial) n3 
dressing*) ) 
S5TI ( (securement device* or Statlock or Hubguard) ) OR AB ( (securement device* or Statlock or 
Hubguard) ) 
S4(MH "Occlusive Dressings") 
S3S1 OR S2 
S2TI ( (peripheral venous catheter* or PVC) ) OR AB ( (peripheral venous catheter* or PVC) ) 
S1(MH "Catheterization, Peripheral+") 
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Figure 1 Risk of bias assessment 
 
 
